Not medical advice. Talk to your provider before using any peptide.
Full disclaimerBPC-157 vs TB-500
Peptide Schedule Research TeamReviewed Apr 202625 Citations
Side-by-side comparison of dosage, benefits, and side effects.
A 2025 systematic review by Vasireddi's group (PMID 40756949) screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were animal studies. One was clinical. That ratio says a lot about where the science stands right now. The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. It promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendons and ligaments. One property separates it from most peptides: it survives stomach acid. Oral dosing works, particularly for gut applications, because the peptide reaches intestinal tissue without being degraded. Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults. Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks. BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. On April 15, 2026, HHS Secretary Kennedy removed BPC-157 and 11 other peptides from Category 2. PCAC review begins July 2026, with compounding access projected for late 2026 to mid-2027. Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.
View full guide →Seven amino acids. That is all TB-500 is. Acetylated leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, pulled from positions 17 through 23 of the 43-amino-acid thymosin beta-4 protein. CAS number 885340-08-9, molecular weight 846.97 Da. The mechanism is well characterized in animals. TB-500 binds monomeric G-actin, sequestering free actin subunits and remodeling the cytoskeleton so that endothelial and immune cells migrate faster to damaged tissue. It upregulates VEGF 2.5 to 3.8-fold. Malinda and colleagues confirmed that thymosin beta-4 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls in corneal wound models (PMID 10469335). It also suppresses myofibroblast differentiation, which reduces scar formation. What makes TB-500 unusual is systemic distribution. You don't need to inject near the injury. Subcutaneous injection in the abdomen reaches a torn rotator cuff the same way it reaches a strained hamstring. Community users have validated this property thousands of times over. The first fragment-specific human trial (NCT07487363) began recruiting in 2026 for an ASCVD indication with approximately 80 subjects. No results are available yet. A 2024 metabolite study by Rahaman and colleagues added a wrinkle: the parent compound showed no wound-healing activity in vitro. The metabolite Ac-LKKTE was the active species. That finding has not changed community dosing practices, but it raises questions about mechanism attribution. Community confidence (4.1/5 sentiment, 500+ r/Peptides threads) sits well ahead of the formal evidence base. TB-500 was on the FDA Category 2 list from 2024 until April 15, 2026, when HHS removed it. Compounding pharmacy access awaits PCAC review starting July 2026. All current supply comes from unregulated gray-market vendors.
View full guide →At a Glance
| Attribute |  BPC-157 |  TB-500 |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Safety Grade | C | C |
| Half-Life | ~30 min plasma (functional tissue activity ~4 hours) | ~5 hours plasma (functional tissue activity persists 7-10 days) |
| Route | Subcutaneous (near injury) or Oral | Subcutaneous or Intramuscular |
| Vial Sizes | 5mg, 10mg | 2mg, 5mg, 10mg |
| Beginner Dose | 250mcg 2x Daily | 2000mcg 2x/week |
| Moderate Dose | 500mcg Daily | 2500mcg 2x/week |
| Aggressive Dose | 500mcg 2x Daily | 5000mcg 2x/week |
| Dosing Source | Community | Community |
| Side Effects | About 30 humans have been formally studied across all BPC-157 publications combined. The published literature calls it well-tolerated. That is accurate for what it covers; it just does not cover much. At standard doses (250 to 500 mcg per day), most users report no problems. The side effect picture changes above 500 mcg per day and in people on SSRIs or SNRIs. Anxiety and panic attacks are the most commonly reported serious community side effects. BPC-157 modulates both dopamine and serotonin systems in animal studies (Sikiric and colleagues, PMID 9073154). Users with pre-existing anxiety disorders and those on serotonergic medications report the highest rates of this effect. Heart palpitations show up repeatedly in community reports, typically in the first few days of a cycle. They tend to clear within a week. Mood changes, including anhedonia, irritability, and a vague sense of feeling "off," affect a subset of users. These track with the dopaminergic and serotonergic modulation in preclinical work. They are more common at higher doses. Insomnia and vivid dreams come up occasionally. Brain fog above 750 mcg per day appears in community reports with no preclinical correlate. Nausea is more frequent with oral dosing. Some users report zero effect. Product quality is the usual explanation. Finnrick Analytics tested 450 samples from 64 vendors; purity ranged from 82 to 100 percent, with 8 percent of samples containing endotoxin contamination. Contraindications: pregnancy and breastfeeding (no reproductive data), active cancer or cancer history (angiogenesis could theoretically feed tumor growth), children under 18 (no pediatric data). The SSRI/SNRI interaction risk warrants a conversation with your prescriber. | TB-500 has never completed a Phase II or Phase III human trial. The only published Phase I (PMID 34346165) tested full 43-amino-acid thymosin beta-4 in 36 healthy Chinese volunteers, not the 7-amino-acid TB-500 fragment. Safety data for the fragment comes almost entirely from community self-reports. Injection site reactions are the most frequently reported problem. Redness, swelling, and tenderness at the injection site appear in a large percentage of users. Rotating between abdomen and thigh reduces local accumulation. Blistering, progressive swelling, or spreading warmth beyond the injection site is abnormal and requires stopping immediately. Fatigue and lethargy during the loading phase (weeks 1 to 2) rank second. Community reports describe this as the most common early side effect at doses of 4 to 5 mg per week. It usually resolves by week 3 without dose adjustment. If fatigue is debilitating, stepping down to 2 mg twice weekly is the standard community recommendation. Headache during loading is common and typically follows the same resolution pattern as fatigue. Nausea is less frequent. Rare but serious reactions include fever above 100.4 degrees F, injection site blistering, skin rash, hives, and muscle aches. Any of these require stopping the protocol and seeking medical evaluation. The unresolved long-term concern is oncogenic risk. TB-500 is pro-angiogenic. It promotes new blood vessel formation. In the presence of occult tumor tissue, this mechanism could theoretically support vascularization and tumor growth. Active cancer or personal cancer history is an absolute contraindication at any dose. Baseline age-appropriate cancer screening (PSA, mammogram, colonoscopy as applicable) is recommended before starting, particularly for anyone over 40. TB-500 is WADA prohibited (S2: Growth Factors) in and out of competition. A 4-year ban was issued in 2024 for documented use. DoD personnel face the same restriction. Pregnancy and breastfeeding: no safety data exists. Do not use. |
Key Differences
- BPC-157 is a 15-amino acid peptide derived from gastric juice, built for targeted gut and tissue repair; TB-500 is a 7-amino acid fragment of Thymosin Beta-4 built for systemic reach.
- BPC-157 works best injected near the injury because its angiogenesis effect concentrates at the injection site; TB-500 works from any injection site because it circulates and migrates to damaged tissue.
- BPC-157 drives angiogenesis and tendon/ligament repair at the site; TB-500 promotes cell migration and calms inflammation body-wide, which is why runners reach for it when several joints hurt at once.
- BPC-157 has a ~2 hour half-life so daily dosing is standard; TB-500 has a ~6 hour half-life, which supports twice-weekly maintenance protocols.
When to Choose BPC-157
- Localized injuries like tendon tears, ligament sprains, or joint pain
- Gut healing and GI issues (BPC-157 was originally isolated from gastric juice)
- When you want targeted repair at a specific site
- Post-surgical recovery for a specific area
When to Choose TB-500
- Systemic inflammation or multiple injury sites
- General recovery and athletic performance
- When injection near the injury site isn't practical
- Cardiac tissue protection or hair growth support
Can You Stack BPC-157 + TB-500?
BPC-157 + TB-500 is the most common injury recovery stack. The two peptides hit different targets. BPC-157 drives angiogenesis and structural repair at the injection site, while TB-500 calms systemic inflammation and speeds cell migration throughout the body. Running them together covers both layers of tissue healing. Many vendors sell it as a pre-mixed blend.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.